BE study designing related doubts [Design Issues]

posted by Helmut Homepage – Vienna, Austria, 2021-03-29 00:41 (19 d 06:55 ago) – Posting: # 22296
Views: 296

Hi gsrao,

» 1). If any molecule intra subject CV of Cmax is less than 30 and for AUC more than 30. in this case can we go for replicate design for EU regulatory?

A replicate design is always accepted.

» 2). For replicate study design which should be preferred partial replicate or full replicate?

From a statistical perspective, a full replicate is preferred. When you are concerned about dropouts or the bioanalytical method requires large sample volumes, opt for one the 2-sequence 3-period designs (TRT|RTR or TRR|RTT).

» which is preferred by regulatory?

Any one is fine. If you opt for a 2-sequence 3-period design you need at least 12 eligible subjects in the sequence where R is repeated (see the Q&A document). That’s not relevant in practice unless you face an extreme dropout-rate (see this post).

» 3). What is the maximum half life to go for Parallel study?

No fixed rules.

» 4). What is the minimum days of wash out period required (in days) for eg. if a molecule half-life is 1 hour?

In days, really? With 1/10 you are on the safe side. :-D
Never plan based on an average. The shortest washout I ever had were three days.

» 5). If a study passes 90 % CI, but the power is below 80 does regulatory approves the study?

Post hoc (a posteriori, retrospective) power is completely irrelevant. Stop calculating it. Stop reporting it. If any agency has – stupid – questions, hire me. See also there.

Dif-tor heh smusma 🖖
Helmut Schütz

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

 Admin contact
21,419 posts in 4,475 threads, 1,508 registered users;
online 8 (0 registered, 8 guests [including 1 identified bots]).
Forum time: Saturday 07:37 CEST (Europe/Vienna)

I never did anything worth doing by accident,
nor did any of my inventions come by accident;
they came by work.    Thomas Alva Edison

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz